These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
919 related articles for article (PubMed ID: 33784491)
1. CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis. Tsoyi K; Liang X; De Rossi G; Ryter SW; Xiong K; Chu SG; Liu X; Ith B; Celada LJ; Romero F; Robertson MJ; Esposito AJ; Poli S; El-Chemaly S; Perrella MA; Shi Y; Whiteford J; Rosas IO Am J Respir Crit Care Med; 2021 Aug; 204(3):312-325. PubMed ID: 33784491 [No Abstract] [Full Text] [Related]
2. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway. Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477 [TBL] [Abstract][Full Text] [Related]
3. Eupatilin inhibits pulmonary fibrosis by activating Sestrin2/PI3K/Akt/mTOR dependent autophagy pathway. Gong H; Lyu X; Liu Y; Peng N; Tan S; Dong L; Zhang X Life Sci; 2023 Dec; 334():122218. PubMed ID: 37918625 [TBL] [Abstract][Full Text] [Related]
4. CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis. Zhang L; Li Y; Liang C; Yang W Int J Mol Med; 2014 Feb; 33(2):478-86. PubMed ID: 24276150 [TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor 21 alleviates idiopathic pulmonary fibrosis by inhibiting PI3K-AKT-mTOR signaling and stimulating autophagy. Qi J; Wu Y; Guo Z; Zhu S; Xiong J; Hu F; Liang X; Ye X Int J Biol Macromol; 2024 Jul; 273(Pt 1):132896. PubMed ID: 38851619 [TBL] [Abstract][Full Text] [Related]
6. Syndecan-2 Attenuates Radiation-induced Pulmonary Fibrosis and Inhibits Fibroblast Activation by Regulating PI3K/Akt/ROCK Pathway via CD148. Tsoyi K; Chu SG; Patino-Jaramillo NG; Wilder J; Villalba J; Doyle-Eisele M; McDonald J; Liu X; El-Chemaly S; Perrella MA; Rosas IO Am J Respir Cell Mol Biol; 2018 Feb; 58(2):208-215. PubMed ID: 28886261 [TBL] [Abstract][Full Text] [Related]
7. SH2 Domain-Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis. Tzouvelekis A; Yu G; Lino Cardenas CL; Herazo-Maya JD; Wang R; Woolard T; Zhang Y; Sakamoto K; Lee H; Yi JS; DeIuliis G; Xylourgidis N; Ahangari F; Lee PJ; Aidinis V; Herzog EL; Homer R; Bennett AM; Kaminski N Am J Respir Crit Care Med; 2017 Feb; 195(4):500-514. PubMed ID: 27736153 [TBL] [Abstract][Full Text] [Related]
8. SPP1 induces idiopathic pulmonary fibrosis and NSCLC progression via the PI3K/Akt/mTOR pathway. Yue B; Xiong D; Chen J; Yang X; Zhao J; Shao J; Wei D; Gao F; Huang M; Chen J Respir Res; 2024 Oct; 25(1):362. PubMed ID: 39369217 [TBL] [Abstract][Full Text] [Related]
9. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis. Espindola MS; Habiel DM; Narayanan R; Jones I; Coelho AL; Murray LA; Jiang D; Noble PW; Hogaboam CM Am J Respir Crit Care Med; 2018 Jun; 197(11):1443-1456. PubMed ID: 29634284 [TBL] [Abstract][Full Text] [Related]
10. Duvelisib attenuates bleomycin-induced pulmonary fibrosis via inhibiting the PI3K/Akt/mTOR signalling pathway. Li X; Ma X; Miao Y; Zhang J; Xi B; Li W; Zhang Q; Chen L; Yang Y; Li H; Wei L; Zhou H; Yang C J Cell Mol Med; 2023 Feb; 27(3):422-434. PubMed ID: 36651446 [TBL] [Abstract][Full Text] [Related]
11. Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis. Barnes JW; Duncan D; Helton S; Hutcheson S; Kurundkar D; Logsdon NJ; Locy M; Garth J; Denson R; Farver C; Vo HT; King G; Kentrup D; Faul C; Kulkarni T; De Andrade JA; Yu Z; Matalon S; Thannickal VJ; Krick S Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L141-L154. PubMed ID: 31042083 [TBL] [Abstract][Full Text] [Related]